Alexion eyes submissions for Soliris in rare CNS disease

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) plans to submit regulatory applications in the U.S., EU and Japan for Soliris eculizumab to treat relapsing neuromyelitis optica spectrum disorder (NMOSD) after the drug met the primary endpoint in the Phase III PREVENT trial in the indication.

The company told BioCentury it is too soon to speculate on specific timing, but said it plans to discuss the data with regulators and prepare submissions as quickly as possible...